HER2-negative breast cancer is a type of breast cancer where the cancer cells don’t contain high levels of a specific protein that normally helps cells grow. This classification plays a crucial role in determining which treatments will work best and understanding how the disease might progress. Most breast cancer cases fall into this category, making it essential for patients and their families to understand what it means and how it affects their care journey.

What is HER2-Negative Breast Cancer?

When doctors examine breast cancer cells under a microscope and in the laboratory, they look for certain markers that tell them how the cancer behaves. One of these markers is a protein called human epidermal growth factor receptor 2, or HER2 for short. This protein sits on the surface of all breast cells and normally helps them grow and repair themselves when needed. In some breast cancers, the cells make too much of this protein, which causes the cancer to grow more aggressively.

HER2-negative breast cancer means that your cancer cells don’t have excess amounts of this HER2 protein. Your healthcare provider determines this status through special tests performed on a small sample of your tumor, usually obtained during a biopsy or surgery. Understanding whether your cancer is HER2-negative or HER2-positive is one of the most important pieces of information your medical team needs to plan your treatment, because certain cancer drugs work by specifically targeting the HER2 protein.

The absence of high HER2 levels doesn’t mean the cancer isn’t serious or doesn’t need treatment. Instead, it means that treatments designed to target HER2 won’t be effective for your particular cancer, and your doctors will focus on other treatment approaches that match your cancer’s specific characteristics.

Types of HER2-Negative Breast Cancer

Not all HER2-negative breast cancers are the same. Doctors classify them into two main groups based on whether the cancer cells respond to hormones. This classification matters because it determines which additional treatments might help control the cancer.

The first type is called HR-positive and HER2-negative breast cancer (also written as HR+/HER2-). This is by far the most common type, accounting for about 70 percent of all breast cancer cases. In this type, the cancer cells have receptors for hormones like estrogen, progesterone, or both. These hormones act like fuel for the cancer, making it grow and spread. Even though these cancers don’t have high levels of HER2, they do respond to hormone levels in your body, which opens up treatment options that work by blocking or lowering these hormones.

The second type is HR-negative and HER2-negative breast cancer (HR-/HER2-), which accounts for about 11 percent of all breast cancer cases. This type is often called triple-negative breast cancer because the cancer tests negative for HER2, estrogen receptors, and progesterone receptors. This means that neither hormones nor HER2 fuel the tumor’s growth. Triple-negative breast cancer requires different treatment approaches because it doesn’t respond to hormone therapy or HER2-targeted treatments.

How Common is HER2-Negative Breast Cancer?

HER2-negative breast cancer is far more common than HER2-positive breast cancer. About four out of every five breast cancers diagnosed don’t have extra HER2 protein. This means that approximately 81 percent of new breast cancer cases are HER2-negative. The vast majority of these cases are hormone receptor positive, meaning they will respond to hormone-based treatments.

It’s worth noting that breast cancer characteristics can sometimes change over time. If your cancer was initially diagnosed as HER2-negative and later comes back or spreads, doctors may test it again because the cancer’s features could potentially be different from the original tumor. This is one reason why ongoing monitoring and follow-up testing remain important throughout your cancer journey.

Symptoms of HER2-Negative Breast Cancer

The symptoms of HER2-negative breast cancer are the same as those of breast cancer in general. Your doctor cannot tell whether your cancer is HER2-negative simply by examining you or based on your symptoms. The HER2 status is only determined through laboratory testing of the tumor tissue.

Common signs to watch for include changes in your breast’s size or shape. You might notice that one breast appears different from the other in ways that weren’t present before. A new lump or hardened area in or near your breast or armpit that doesn’t change with your menstrual cycle should always be evaluated by a healthcare provider.

Skin changes affecting your breast or nipple can also signal breast cancer. These might include skin that appears dimpled or puckered, similar to the texture of an orange peel. The skin might become scaly, itchy, or change color, appearing reddish, purple, or unusually dark. Any discharge from your nipple, whether bloody or clear, warrants medical attention. A nipple that suddenly pulls inward or changes position is another warning sign.

What Causes HER2-Negative Breast Cancer?

HER2-negative breast cancer develops when the DNA inside breast cells undergoes changes, or mutations, that transform normal cells into cancer cells. Once these mutations occur, the cells begin to divide uncontrollably and form tumors. Scientists and doctors don’t yet fully understand what triggers these specific DNA changes that lead to HER2-negative breast cancer, but they continue to research this important question.

What researchers do know is that breast cancer isn’t caused by a single factor. It’s not something you catch from another person like a cold, and it’s not caused by an injury to your breast. The disease develops through a complex interaction of genetic, biological, and environmental factors that accumulate over time.

Risk Factors for HER2-Negative Breast Cancer

While doctors can’t pinpoint the exact cause of HER2-negative breast cancer in most cases, they have identified several factors that increase a person’s risk of developing breast cancer in general. Understanding these risk factors can help you and your healthcare provider make informed decisions about screening and prevention.

Inherited genetic mutations play a significant role in breast cancer risk. While there isn’t a specific mutation that causes only HER2-negative breast cancer, inheriting mutations in genes like BRCA1 or BRCA2 substantially increases your overall risk of developing breast cancer. If you have a family history of breast cancer, especially among close relatives like a parent, sibling, or child, your own risk increases. Having had breast cancer once also raises your chances of developing it again, either in the same breast or the other one.

Long-term exposure to high levels of estrogen or progesterone affects breast cancer risk. Women who started their menstrual periods at an early age or began menopause later in life have longer lifetime exposure to these hormones. Some forms of hormone replacement therapy, particularly those containing both estrogen and progesterone taken for extended periods, can also increase risk.

Lifestyle factors influence breast cancer risk as well. Being overweight or obese, especially after menopause, increases risk because fat tissue produces estrogen. Physical inactivity contributes to higher risk, while regular exercise appears to offer some protection. Alcohol consumption raises breast cancer risk, and the more you drink, the higher the risk becomes. Even moderate drinking of three to six glasses per week increases risk compared to not drinking at all.

Age is one of the strongest risk factors for breast cancer. The disease becomes more common as women get older, with most cases diagnosed in women over age 50. However, younger women can also develop breast cancer, and triple-negative breast cancer in particular tends to affect younger women more often than other types.

How is HER2-Negative Breast Cancer Diagnosed?

Determining whether breast cancer is HER2-negative requires laboratory testing of tumor tissue. Your doctor cannot tell your HER2 status through a physical examination alone. The testing process begins with obtaining a sample of the tumor, which usually happens during a biopsy or surgical procedure where a piece of the suspicious tissue is removed for analysis.

In the laboratory, specialists perform tests on this tissue sample to measure the amount of HER2 protein present. The test results tell your medical team whether the cancer cells have excess HER2 protein (HER2-positive) or don’t have high levels of it (HER2-negative). This information becomes part of your complete breast cancer diagnosis, along with other important characteristics like the cancer’s stage, grade, and hormone receptor status.

Understanding your breast cancer’s HER2 status, together with its hormone receptor status, gives you and your doctors crucial information about the biology of your cancer. This knowledge helps guide treatment decisions, determining which therapies are most likely to work and which ones won’t be effective. It also provides insight into how aggressively the cancer might behave and what your outlook might be.

Prevention Strategies

While you cannot completely prevent breast cancer, certain lifestyle choices may help reduce your risk. Maintaining a healthy weight through balanced nutrition and regular physical activity plays an important role. Exercise not only helps control weight but also appears to have independent protective effects against breast cancer. Experts recommend at least 150 minutes of moderate-intensity activity or 75 minutes of vigorous activity each week.

If you drink alcohol, limiting your consumption can reduce your breast cancer risk. For women who choose to drink, keeping intake low—ideally no more than one drink per day—is advisable. Quitting smoking also contributes to better overall health and may reduce cancer risk.

For women with very high breast cancer risk due to genetic factors or family history, preventive measures might include more intensive screening, medications that lower risk, or even preventive surgery in some cases. These decisions are highly personal and should be made in consultation with healthcare providers who specialize in cancer genetics and high-risk care.

Regular breast cancer screening remains one of the most effective ways to catch cancer early, when it’s most treatable. For most women, this means having mammograms according to recommended schedules, typically starting at age 40 or 50 depending on risk factors and following your healthcare provider’s guidance. Women at higher risk may need to start screening earlier or have additional tests like breast MRI.

How HER2-Negative Breast Cancer Affects the Body

Understanding what happens in the body when HER2-negative breast cancer develops helps explain why certain symptoms occur and how treatments work. In normal breast tissue, cells grow, divide, and die in an orderly, controlled way. The HER2 protein participates in this process by helping cells know when to grow and when to stop growing.

In HER2-negative breast cancer, even though the cells don’t have excess HER2 protein, something has gone wrong with the normal control mechanisms that regulate cell growth. In hormone receptor-positive cases, the cancer cells have learned to use estrogen or progesterone as signals to keep growing. These hormones, which normally help regulate various bodily functions, now inadvertently fuel cancer growth. The cancer cells multiply more rapidly than normal cells, and they don’t die when they should.

As cancer cells accumulate, they form a mass or tumor. These abnormal cells can invade nearby breast tissue, destroying normal, healthy tissue as they spread. If not treated, cancer cells can break away from the original tumor and travel through the lymphatic system or bloodstream to other parts of the body. When cancer spreads to distant organs, this is called metastasis, and the disease becomes much more challenging to treat.

In triple-negative breast cancer, the situation is somewhat different. These cancers don’t rely on hormones or HER2 for growth, which means they’ve found other pathways to drive their aggressive behavior. This makes them particularly challenging to treat because they don’t respond to the hormone therapies or HER2-targeted drugs that work for other breast cancer types. However, researchers continue to discover new vulnerabilities in these cancers that can be targeted with emerging treatments.